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Abstract
Thoracic aortic aneurysms (TAAs) are permanent pathological dilatations of the thoracic aorta, which can lead to life-threatening
complications, such as aortic dissection and rupture. TAAs frequently occur in a syndromic form in individuals with an
underlying genetic predisposition, such as Marfan syndrome (MFS) and Loeys-Dietz syndrome (LDS). Increasing evidence
supports an important role for transforming growth factor-β (TGF-β) and the renin-angiotensin system (RAS) in TAA pathol-
ogy. Eventually, most patients with syndromic TAAs require surgical intervention, as the ability of present medical treatment to
attenuate aneurysm growth is limited. Therefore, more effective medical treatment options are urgently needed. Numerous
clinical trials investigated the therapeutic potential of angiotensin receptor blockers (ARBs) and β-blockers in patients suffering
from syndromic TAAs. This review highlights the contribution of TGF-β signaling, RAS, and impairedmechanosensing abilities
of aortic VSMCs in TAA formation. Furthermore, it critically discusses the most recent clinical evidence regarding the possible
therapeutic benefit of ARBs andβ-blockers in syndromic TAA patients and provides future research perspectives and therapeutic
implications.
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Introduction: Thoracic Aortic Aneurysms
Thoracic aortic aneurysms (TAAs) are permanent pathologic
dilatations of the thoracic aorta leading to an increase of more
than 50% of the normal aortic diameter [1]. Although expan-
sion of the aneurysm is asymptomatic, TAAs can suddenly
lead to life-threatening complications, such as aortic dissec-
tion and aortic rupture [2]. In most TAAs, the risk of these
possibly fatal events is directly proportional to the size of the
aneurysm [3, 4]. Therefore, aneurysm diameter is strictly
monitored in affected patients and medical therapy is initiated
in an attempt to slow down TAA expansion. Most often, β-
adrenergic blockers (β-blockers) are prescribed to decrease
blood pressure, cardiac contractility and shear stress on the
aorta, however at variable efficacy [5]. If the aneurysm diam-
eter exceeds certain dimensions, timely prophylactic surgical
or endovascular intervention is necessary. Generally, an aneu-
rysm diameter between 50 and 55 mm is regarded as indica-
tion for intervention; however, some patients require surgery
at smaller diameters depending on underlying conditions and
hereditary factors [5]. Several risk factors for the development
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of TAAs have been identified, such as smoking and hyperten-
sion [1].
Although themajority of TAAs are sporadic, approximately
20% of TAAs occur in a syndromic or familial form in indi-
viduals with an underlying genetic predisposition [6, 7]. The
most notable of these TAA syndromes are Marfan syndrome
(MFS) and Loeys-Dietz syndrome (LDS), in which TAAs will
develop in a high proportion of the affected individuals [8, 9].
Over the past 2 decades, both preclinical and clinical studies
identified pathophysiological mechanisms that lead to TAAs,
particularly in MFS patients. Substantial evidence demon-
strates that increased signaling of the transforming growth
factor-β (TGF-β) pathway plays an important role in thoracic
aortic pathology [10, 11]. Nonetheless, the exact contribution
of TGF-β signaling to TAA pathogenesis remains subject of
debate [10, 12]. Additionally, the renin-angiotensin system
(RAS) interacts with TGF-β signaling on multiple levels [13]
and is also shown to constitute an important contributor to
TAA formation [14, 15]. More recently, impairments in cellu-
lar responses to progressive hemodynamic aortic load
(mechanosensing and mechanotransduction) in syndromic in-
dividuals have been put forward to predispose to hereditary
TAAs [16, 17]. Multiple studies have investigated the thera-
peutic potential of compounds that inhibit TGF-β signaling or
the RAS-TGF-β interaction in the context of TAAs, such as
TGF-β neutralizing antibodies or angiotensin receptor
blockers (ARBs). This review focuses on the role of TGF-β
signaling and its interactions with RAS in syndromic TAA
formation. Subsequently, the most recent clinical evidence
concerning the usage of ARBs and β-blockers to attenuate
aneurysm expansion is highlighted and critically discussed.
Finally, future research perspectives and clinical implications
are provided for affected TAA patients.
The TGF-β Signaling Pathway and Its Role
in TAA Development
TGF-β signaling plays a critical role in multiple biological
processes, including cellular growth, differentiation, apoptosis,
migration and extracellular matrix (ECM) production [18].
Three homologous TGF-β isoforms exist (TGF-β1, TGF-β2,
and TGF-β3), which are produced by multiple cell types as
precursor proteins [19]. Increasing evidence suggests different
physiological roles of these isoforms and mutations in TGF-β2
and TGF-β3 have been associated with TAA formation
[20–23]. However, most studies in the context of thoracic aortic
pathology did not discriminate between these three isoforms
and this review will therefore refer to these isoforms collective-
ly as “TGF-β", unless stated otherwise. After intracellular
cleavage, TGF-β remains associated with the cleaved part,
the latency-associated peptide (LAP), through non-covalent
interaction. Together they constitute the small latent complex
(SLC). In turn, the latent TGF-β binding protein (LTBP) inter-
acts with LAP to form a large latent complex (LLC) before
being secreted by the cell [24]. After secretion, LTBPs interact
with several constituents of the ECM, including fibrillin micro-
fibrils [25]. In this way, TGF-β is sequestered in the ECM,
which serves as an important TGF-β reservoir. Originally,
fibrillin-1 was described as a structural component of the
ECM [26], but more recently it was found that fibrillin-1 can
also regulate the bioavailability of TGF-β1 by displacing the
latency complex from microfibrils [27]. Besides, matrix metal-
loproteinases (MMPs), integrin presentation, reactive oxygen
species, and thrombospondin-1 are involved in regulating re-
lease from the LLC [28–33].
After its release and activation, TGF-β causes assembly of
the TGF-β receptor complex, which consists of two TGF-β
receptors I (TGFBR1) and two TGF-β receptors II
(TGFBR2). Binding of active TGF-β to TGFBR2 recruits
TGFBR1, which becomes activated through phosphorylation
by the constitutively active TGFBR2-kinase domain.
Subsequently, this signal is propagated to downstream intra-
cellular signaling cascades, which can be divided into one
canonical and multiple non-canonical pathways [34–36]
(Fig. 1). Interestingly, both canonical and non-canonical sig-
naling pathways have been shown to be involved in TAA
development [37–40].
Canonical TGF-β Pathway
The canonical TGF-β pathway is also known as the SMAD
(Small Mothers Against Decapentaplegic)-dependent TGF-β
pathway, in which the activated TGF-β receptor phosphorylates
SMAD2 and SMAD3, the so-called receptor-regulated SMADs
or R-SMADs (Fig. 1). Once phosphorylated, the R-SMADs
have a high affinity to form a heterotrimeric complex with
SMAD4 or co-SMAD. These SMAD complexes translocate
to the nucleus where they interact with promotors/co-factors to
regulate the transcription of downstream target genes [41–46].
These target genes are involved in the regulation of numerous
processes, including ECM turnover, apoptosis and cellular
proliferation, differentiation, motility and adhesion [10, 47].
Two inhibitory SMADs (I-SMADs), SMAD6 and SMAD7,
are part of a negative feedback loop to regulate TGF-β sig-
naling (Fig. 1). Both I-SMADs can inhibit TGF-β signaling
and bone morphogenetic protein (BMP) signaling, although
the effect of SMAD6 is modest [48, 49]. Increased TGF-β
signaling correlates with increased expression of these I-
SMADs, suggesting that their transcription is regulated down-
stream of the TGF-β pathway [50–52]. In addition, the SKI
oncogene (SKI) protein inhibits the TGF-β pathway by re-
pression of SMAD protein activity (Fig. 1) [53].
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Non-canonical TGF-β Pathways
TGF-β signaling additionally acts via four non-canonical
(SMAD-independent) pathways: ERK1/2, JNK/p38,
PI3K/Akt, and small GTPase [54] (Fig. 1). The first three of
these pathways result in the activation of transcription factors
that regulate apoptosis and epithelial-to-mesenchymal transi-
tion (EMT), often in concert with SMADs [54]. During EMT,
epithelial cells differentiate into mesenchymal cells through
the loss of polarity and cell-cell adhesions and acquire the
capability to migrate, proliferate and differentiate. Although
mesenchymal cells play a key role in tissue repair, they can
also induce pathology by stimulation of tissue fibrosis [55].
Pathological EMT is predominantly associated with tumor
metastasis, but this process also affects the integrity of the
aortic ECM by promoting fibrosis and expression of MMPs,
possibly contributing to TAA formation [36, 46]. The small
GTPase pathway is involved in dissolution of tight junctions
and cell adhesion. Furthermore, it stimulates the formation of
membrane protrusion and induces, via Ras homology family
member A (RhoA), actin polymerization and stress fiber for-
mation. This again affects EMT in concert with SMAD sig-
naling, as SMAD also stimulates RhoA [54].
Crosstalk of Canonical TGF-β Pathway and Non-
canonical TGF-β Pathways
Multiple modes of crosstalk between canonical and non-
canonical TGF-β signaling can be distinguished. Both
ERK1/2 and JNK are capable of phosphorylating R-SMADs
to alter their activities, and the PI3K/Akt pathway can directly
influence the net outcome of SMAD signaling [40, 54]. In
turn, inhibitory SMADs have been demonstrated to regulate
ERK and JNK/p38 signaling [56]. In this way, complex inter-
actions are established, and their net outcomes are often highly
dependent on the cellular context in which they occur. Next to
direct interactions, another important crosstalk between ca-
nonical and non-canonical TGF-β signaling occurs at the lev-
el of DNA transcription. An example concerns the Smad3/4
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Fig. 1 Overview of the TGF-β
signaling pathway. After cellular
secretion, TGF-β is sequestered
in the ECM as the large latent
complex (LLC). Upon release
from the LLC, TGF-β binds, as-
sembles, and activates the TGF-β
receptor. Activation of this recep-
tor complex initiates canonical
and multiple non-canonical TGF-
β signaling pathways. From left
to right the canonical pathway,
ERK1/2 pathway, JNK/p38 path-
way, PI3K/Akt pathway, and
small GTPase pathway
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synergistic co-modulators of transcription of multiple TGF-β
target genes. The extensive connections between the canoni-
cal and non-canonical TGF-β signaling pathways and the
processes that are regulated by their crosstalk are reviewed
in more detail elsewhere [56].
TGF-β Pathway Genes Associated with Aneurysm
Formation
TAAs are associated with a wide range of genetic mutations,
which can broadly be classified into 3 main groups: genes
encoding ECM constituents, genes involved in the contractile
apparatus of vascular smooth muscle cells (VSMCs) and
genes involved in the TGF-β pathway [57]. Table 1 gives an
overview of important genetic defects leading to TAA forma-
tion and associated syndromes and phenotypes.
The most notable in the first group are mutations in the
FBN1 gene, encoding the fibrillin-1 protein. Mutations in
FBN1 cause MFS, an autosomal dominant connective tissue
disorder [58–60]. As fibrillin-1 is a principal component of the
extracellular microfibrils, abnormal or deficient production of
this protein distorts structural integrity of the ECM [61].
Besides, FBN1 mutations are demonstrated to hamper
TGF-β sequestration in the ECM, which leads to enhanced
TGF-β bioavailability and increased activation of TGF-β sig-
naling [27, 62]. Clinically, MFS is characterized by aortic
aneurysms mainly located at the level of the aortic root and
multiple cardiovascular, skeletal, and ocular manifestations,
such as prolapse of the atrioventricular valves, anterior chest
deformity, arachnodactyly, myopia, and ectopia lentis [8, 58,
59]. Importantly, aortic dissections occur in up to 70% ofMFS
patients and constitute the main cause of premature death [63].
Table 1 Genetic defects causing aortic aneurysms in human
Gene Protein Chromosomal
locus
Disease Main clinical features Reference
FBN1 Fibrillin-1 15q21.1 Marfan syndrome Aortic root aneurysm and dissection, ectopia lentis,
myopia, pectus deformity, arachnodactyly
[58, 59]
BGN Biglycan Xq28 Meester-Loeys syndrome Early-onset aortic aneurysm and dissection,
hypertelorism, pectus deformity, joint












9q22.33 Loeys-Dietz syndrome type I Widespread and aggressive arterial aneurysms and
dissections, arterial tortuosity, hypertelorism, cleft




3p24.1 Loeys-Dietz syndrome type
II
Widespread and aggressive arterial aneurysms and
dissections, arterial tortuosity, hypertelorism, cleft
palate, bifid uvula, pectus deformity, scoliosis
[68]
SMAD3 Small mothers against
decapentaplegic
homolog 3
15q22.33 Loeys-Dietz syndrome type
III (also known as
aneurysm-osteoarthritis
syndrome)
Widespread and aggressive arterial aneurysms and






1q41 Loeys-Dietz syndrome type
IV
Thoracic aortic aneurysm and dissection, arterial
tortuosity, mitral valve prolapse, arachnodactyly,




14q24.3 Loeys-Dietz syndrome type
V
Aortic aneurysm and dissection, mitral valve
prolapse, hypertelorism, arachnodactyly, cleft
palate, bifid uvula, pectus deformity, scoliosis
[22]
SMAD2 Small mothers against
decapentaplegic
homolog 2
18q21.1 Loeys-Dietz syndrome type
VI
Arterial aneurysms and dissections, valve
abnormalities, hypertelorism, pectus deformity,
scoliosis, osteoarthritis, hernias
[71, 72]
SMAD4 Small mothers against
decapentaplegic
homolog 4
18q21.2 Haemorrhagic telangiectasia Gastrointestinal hamartomatous polyps, cutaneous
and mucosal telangiectasia, epistaxis,
arteriovenous malformations
[77]






Bicuspid aortic valve, thoracic aortic aneurysm [80]
SKI Ski oncogene 1p36.33-p36.32 Shprintzen-Goldberg
syndrome
Craniosynostosis, hypertelorism, high palate,
micrognathia, arachnodactyly, joint contractures,
pectus deformity, hypotonia, developmental delay
[78, 79]
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Another prominent example of this first group of mutations
are mutations in BGN, encoding biglycan, a small proteogly-
can involved in assembly and maintenance of the ECMwhich
is known to interact with TGF-β [64]. Lack of functional
biglycan results in increased TGF-β bioavailability, mainly
in the vascular adventitia layer which is the major site of
biglycan deposition [65]. Patients with BGN mutations are
characterized by early-onset aortic aneurysms and aortic dis-
sections, hypertelorism, pectus deformity, joint hypermobili-
ty, contractures, and mild skeletal dysplasia [64]. Lastly, mu-
tations in EFEMP2 lead to impaired function of the EGF-
containing fibulin-like extracellular matrix protein 2, better
known as fibulin-4. Fibulin-4 interacts with multiple ECM
components and is involved in elastogenesis, cross-linking,
and regulation of TGF-β activity. Fibulin-4 mutations cause
cutis laxa type 1B, which is a syndromic autosomal recessive
condition characterized by aortic aneurysms, non-elastic loose
skin (cutis laxa), vascular deformities, aneurysms, joint laxity
and arachnodactyly [66, 67].
Examples of mutations in contractile apparatus genes lead-
ing to TAA are smooth muscle cell-specific isoforms of α-
actin (ACTA2) and myosin heavy chain (MYH11). Mutations
in these genes result in non-syndromic TAA and are reviewed
elsewhere [16].
This review particularly focuses on genetic mutations af-
fecting the TGF-β pathway that lead to TAA formation. In the
past 2 decades, numerous mutations in genes encoding pro-
teins of the TGF-β pathway were discovered to be associated
with aneurysm formation. Notably, different mutations in the
TGF-β pathway cause LDS, an autosomal dominant connec-
tive tissue disorder. LDS can be classified into six different
subtypes, according to the underlying mutation (TGFBR1,
TGFBR2, SMAD3, TGFB2, TGFB3, and SMAD2) [21, 22,
68–73]. LDS patients share many phenotypical characteristics
with MFS patients, but LDS vascular pathology is often
more aggressive and more widespread, affecting the entire
arterial tree. This includes widespread arterial tortuosity
and aneurysms of various medium-to-large muscular arter-
ies, including the aorta and cerebral arteries [74].
Importantly, aortic aneurysms tend to dissect at smaller
diameters and at a younger age [74, 75] and a high propor-
tion of the affected individuals eventually require surgical
intervention [76]. In addition, mutations in SMAD4 and in
SKI, an inhibitor of the TGF-β pathway, cause hemorrhag-
ic telangiectasia and Shprintzen-Goldberg syndrome re-
spectively. Both conditions are associated with thoracic
aortic pathology, although this is less common than in
MFS and LDS [77–79]. Besides, mutations in SMAD6,
another inhibitor of TGF-β signaling, are associated with
bicuspid aortic valve and TAA [80]. Altogether this high-
lights the essential role of the TGF-β pathway in cardio-
vascular diseases, particularly, but not limited to, the for-
mation of TAAs.
Mouse Models for TAA
The identification of genes responsible for heritable TAAs
enabled the generation of mouse models with a TAA pheno-
type (Table 2). Of note, the exact TAA phenotypes vary con-
siderably, due to differences in genetic background.
Nonetheless, these mouse models allowed not only a more
in-depth analysis of the effects of these different genetic mu-
tations but also an evaluation of different potential treatment
modalities targeting aneurysm growth.
Firstly, several mouse models for MFS exist, harboring
mutations in Fbn1. Fbn1mgN/mgN and Fbn1GT-8/GT-8 mice lack
Fbn1 expression, Fbn1mgΔ/mgΔ mice have 10-fold reduced
Fbn1 expression and Fbn1mgR/mgR have 4- to 5-fold reduced
Fbn1 expression [81–84]. Finally,Fbn1C1041G/+micemimic a
patient missense mutation (C1039Y), which results in reduced
formation of fibrillin-1 fibers, despite normal Fbn1 expression
[85]. Of note, Fbn1mgN/mgN, Fbn1GT-8/GT-8 mice, and
Fbn1mgΔ/mgΔ mice die in the first weeks of life, whereas ho-
mozygous Fbn1mgR/mgR mice die around 4–6 months due to
aortic dissections [81–84]. Although MFS patients nowadays
have near-normal lifespan [86], the average life expectancy
for MFS patients in 1972, before the evolution of open-heart
surgery, was reported to be 32 years and most patients died
due to aortic dissections [87, 88]. This phenotype is mostly
phenocopied by untreated Fbn1mgR/mgR mice. In contrast,
Fbn1C1041G/+ mice have a normal life span [85]. This could
imply that lower expression of Fbn1 results in a more severe
phenotype.
Secondly, several mouse models for LDS have been
established. Full knock-out models for Tgfbr1, Tgfbr2 and
Smad3 were generated, as well as mice with a conditional
knock-out of Tgfbr1 and Tgfbr2 specifically in the endotheli-
um, VSMCs or neural crest [39, 89–95]. In addition, a mouse
model with a postnatal SMC-specific Tgfbr2 deletion and
Tgfbr1M318R/+ and Tgfbr2G257W/+ mouse models with hetero-
zygous kinase-inactivating missense mutations were created
[96–98]. Smad3 knock-out mice develop aneurysms and his-
tological analysis of TAA tissue reveal fragmentation of the
elastic laminae and aortic immune infiltration, similar to the
alterations observed in the human situation [39, 89].
Conventional knock-outs for Tgfbr1 or Tgfbr2 and conditional
knock-outs for Tgfbr1 or Tgfbr2 in endothelial cells or
VSMCs are embryonic lethal, due to serious defects in vascu-
lar development [90–92]. Conditional knock-out of Tgfbr1 or
Tgfbr2 is lethal during birth or in the immediate postnatal
period [93–95]. Postnatal SMC-specific Tgfbr2 deletion re-
sults in vascular abnormalities, which are also found in LDS
patients [98]. Tgfbr1M318R/+ and Tgfbr2G257W/+mice have car-
diovascular and craniofacial abnormalities, partly overlapping
with the characteristics of LDS patients [96, 97].
Thirdly, several mouse models harboring mutations in
Fbln4, encoding fibulin-4, have been created. As mentioned,
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fibulin-4 plays an important role in elastic fiber formation and
mutations in EFEMP2 (the human gene encoding fibulin-4)
cause cutis laxa type 1b. Importantly, a complete knock-out of
Fbln4 (Fbln4−/−) results in perinatal death [99]. In order to
generate a more viable mouse model, a VSMC-specific
knock-out (Fbln4f/−/SM22Cre+) was generated, in which an-
eurysms in the ascending aorta develop rapidly, accompanied
by fragmentation of the elastic laminae [100–102]. Besides,
Fbln4R/R mice, expressing only 25% of fibulin-4 compared to
wild-type mice, present with aneurysms throughout the entire
aorta, fragmentation of the elastic lamina, and increased ECM
deposition. In these mice, increased upstream and downstream
TGF-β signaling was detected by elevated levels of TGF-β
ligand, increased SMAD2 phosphorylation and increased ac-
tivation of the downstream target plasminogen activator
inhibitor-1 (PAI-1) [103, 104]. Lastly, Fbln4E57K/E57K mice
express a mutated form of fibulin-4, which impairs binding
to LTBP1 and reduces assembly of the ECM. Similarly, this
results in aneurysm formation and fragmentation of elastic
laminae [67, 105].
The Role of TGF-β Signaling in TAA
Over the years, dysregulation of TGF-β signaling has been
proposed in multiple TAA syndromes. Neptune et al. were the
first to propose a detrimental role of TGF-β signaling inMFS,
Table 2 Genetic mouse models for thoracic aortic aneurysms
Gene Mouse model Expression Phenotype References
Fbn1 Fbn1mgN/mgN No Fbn1 expression Postnatal death within 2 weeks due to ruptured aortic aneurysm,
impaired pulmonary function, and/or diaphragmatic collapse,
aneurysms mainly located in the ascending aorta
[81]
Fbn1mgΔ/mgΔ 10-fold reduced Fbn1
expression
Postnatal death within 3 weeks of age due to cardiovascular
complications
[82]
Fbn1GT-8/GT-8 No significant Fbn1
expression
Postnatal death within 3 weeks of age [83]
Fbn1mgR/mgR 4- to 5-fold reduced Fbn1
expression
Average lifespan of 4 months, aneurysm formation and
dissection/rupture, pulmonary insufficiency
[84]
Fbn1C1041G/+ Missense mutation, normal
expression
Normal lifespan, aortic aneurysm formation [85]
Smad3 Smad3−/− No Smad3 expression Sudden death between 6 and 30 weeks of age due to thoracic
aneurysmal dissection or cardiac tamponade, aneurysm
formation in aorta and other vessels, increased aortic length,
fragmentation of the elastic laminae, immune cell filtration
[39, 89]




No Tgfbr1 expression in
specific cell types
Endothelium and VSMC specific: embryonically lethal, severe
defects in vascular development
Neural crest specific: lethal during birth or postnatal-hours, severe
cardiovascular and pharyngeal defects
[90, 93]
Tgfbr1M318R/+ Missense mutation, normal
expression
Predisposition to aortic dissection and early death, aortic root
aneurysm, tortuosity, elastic fiber fragmentation, craniofacial
and skeletal abnormalities
[96, 97]




No Tgfbr2 expression in
specific cell types
Endothelium and VSMC specific: embryonically lethal, severe
defects in vascular development






95% reduction of Tgfbr2
expression after
tamoxifen treatment
Aortic dilatation, dissection, hemorrhage and ulceration,
elastolysis, macrophage infiltration, abnormal proteoglycan
accumulation
[98, 115]
Tgfbr2G257W/+ Missense mutation, normal
expression
Predisposition to aortic dissection and early death, aortic root
aneurysm, tortuosity, elastic fiber fragmentation, craniofacial
and skeletal abnormalities
[97]
Fbln4 Fbln4−/− No Fbln4 expression Early postnatal death, arterial tortuosity, aortic aneurysm formation
and rupture
[99]
Fbln4f/−/SM22Cre+ No Fbln4 expression in
VSMCs
Reduced lifespan, aneurysm formation, fragmentation of the elastic
laminae
[100–102]
Fbln4R/R 4-fold reduced Fbln4
expression
Sudden death within first 3 weeks of life, aneurysm formation and
dissection
[103, 104]
Fbln4E57K/E57K Missense mutation, normal
expression
Aneurysm formation, fragmentation of the elastic laminae [67, 105]
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as they demonstrated that mice deficient in fibrillin-1
(Fbn1mgΔ/mgΔ) have upregulated TGF-β activation and sig-
naling. This led to impaired lung development due to in-
creased cellular apoptosis [27]. As these Fbn1mgΔ/mgΔ mice
die around postnatal day 12, a Fbn1 mouse model with a
missensemutation (Fbn1C1041G/+) was created to enable better
analysis of aneurysm development. In this model, Habashi
et al. demonstrated that increased TGF-β signaling, based
on increased pSMAD2 levels, is associated with TAA devel-
opment [106]. Additional evidence for the involvement of
TGF-β signaling in TAA was the finding that mutations in
TGF-β pathway genes also predispose to TAA, such as in
LDS patients (Table 1). Remarkably, most of these mutations
constitute loss-of-function mutations, but yet seem to enhance
TGF-β signaling [107]. Indeed, nuclear accumulation of
phosphorylated SMAD2 and SMAD3 and increased expres-
sion of TGF-β-regulated genes was found in LDS patients
with TGFBR1 and TGFBR2 mutations. This is indicative of
upregulated TGF-β signaling [68, 108, 109]. Indeed,
pSMAD2 activation is often used as a readout for TGF-β
activation [22, 97, 106]. Interestingly, upregulated TGF-β
signaling is also observed with mutations in the other genes
that cause LDS, such as TGFB2, TGFB3, and SMAD3 [21, 22,
70]. How this paradoxically elevated TGF-β signaling,
known as “the TGF-β paradox", is mediated at a functional
level is still not fully understood. One potential explanation
for the TGF-β paradox, observed in in Smad3−/− mice, is that
these genetic mutations lead to increased upstream canonical
TGF-β signaling (pSMAD2), without affecting downstream
canonical TGF-β signaling [39]. In addition, mutations in
FBN1 and EFEMP2 were found to indirectly affect TGF-β
signaling [103, 110]. In turn, excessive TGF-β signaling in
adult aorta has been linked to improper remodeling of the
vascular ECM, VSMC dysfunction and TAA development
[111, 112]. Excessive TGF-β signaling also leads to increased
expression and activity of MMPs, degradation of elastic fi-
bers, enhanced proliferation and migration of VSMCs and
excessive secretion and deposition of collagens [111, 113].
These effects could all contribute to weakening of the aortic
wall, rendering it more vulnerable for dilation, dissection and
rupture [111].
Interestingly, treatment with TGF-β-neutralizing antibod-
ies, from 7 to 15weeks of age, normalized TGF-β signaling in
the aortic media and improved elastic fiber fragmentation and
aortic wall architecture in Fbn1C1041G/+ mice. Also, this treat-
ment reduced aortic wall thickness and attenuated growth of
the aortic root [106]. This indicates that excessive TGF-β
signaling contributes to the formation of aortic aneurysms
and that TGF-β antagonism is a potential treatment strategy.
Importantly, it has been shown that adequate timing of TGF-β
neutralization is essential. In Fbn1mgR/mgR mice, a beneficial
effect of TGF-β neutralization was observed when the treat-
ment was started after onset of aneurysm formation (8-week
old mice). However, if treatment with TGF-β-neutralizing
antibodies was started before onset of aneurysm formation
(postnatal day 16), this led to an acceleration in aneurysm
development [114]. Besides, prenatal VSMC-specific
Tgfbr2 deletion in mice results in defective elastogenesis, ves-
sel wall dilatation, aneurysms, and dissections [94, 115, 116].
In contrast, these harmful effects did not occur when this
VSMC-specific Tgfbr2 deletion was induced in mice at the
age of 8-weeks [115]. This indicates that TGF-β has a protec-
tive role against aneurysm formation early in vascular devel-
opment. Indeed, the TGF-β signaling pathway has been dem-
onstrated to play an essential role in the initial vascular forma-
tion during embryogenesis, as mice with a knock-out mutation
in either Tgfb1, Tgfbr1, or Tgfbr2 developed severe defects in
yolk sac vasculogenesis and hematopoiesis [117], predispos-
ing to early embryonic lethality [90]. Also, TGF-β signaling is
important for the formation of the embryonic vascular plexus,
proper elastogenesis during embryogenesis and during the
first weeks of life and for the development, morphogenesis
and migration of endothelial cells and VSMCs [111, 118,
119]. Once these processes are completed, TGF-β seems to
switch to become a detrimental contributor to aortic pathology
[106, 111, 114], as reflected by the observed beneficial effects
of TGF-β neutralization in a later stage [106]. Thus, adequate
timing of TGF-β neutralization seems essential to optimally
benefit from its protective effects on TAA formation, sparing
the early protective role of TGF-β signaling [114]. However,
the consequences of TGF-β neutralization on aortic pathology
also seems to be dependent on the animal model studied. In a
mouse model in which aortic aneurysm formation was in-
duced by continuous administration of angiotensin II (Ang
II), concomitant treatment with a TGF-β neutralizing anti-
body promoted aortic rupture, mostly at the level of the as-
cending aorta and suprarenal aortic region. In contrast, treat-
ment with a TGF-β neutralizing antibody after the Ang II
treatment period had no detrimental effects on aortic morphol-
ogy [120]. This again stresses the variable effects of TGF-β
neutralization at different developmental timepoints.
Another observation that adds to the complexity of the
exact role of TGF-β in aneurysm formation was described
by MacFarlane et al. In their study, they found that the effect
of the Tgfbr1mutation, and subsequent disturbance in TGF-β
signaling in the Tgfbr1M318R/+ LDS mouse model, varies be-
tween VSMCs that are derived from distinct lineages of ori-
gin. Their study suggests that the predisposition to aortic root
aneurysm in LDS mice depends on both defective SMAD
signaling in secondary heart field–derived VSMCs and exces-
sive SMAD signaling in cardiac neural crest-derived VSMCs
[96]. This is in line with previous findings in avian systems,
which show that neural crest– and mesoderm-derived VSMCs
respond differently to TGF-β1. To be more precise, cellular
proliferation and fibrosis were seen in the neural crest-derived
VSMCs and growth inhibition in the mesoderm-derived
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VSMCs [106, 121, 122]. Although this concept has not been
further verified in other aortic aneurysm syndromes, perturba-
tions in TGF-β signaling could thus have different effects on
the various cell types that comprise the aortic tissue.
In summary, combinatory evidence from TAA mouse
models and human genetic studies reveals a dimorphic role
of TGF-β signaling in the development of TAA. During em-
bryogenesis and in the first weeks of life, it has protective
effects, whereas at a later time point it is an important contrib-
utor to thoracic aortic pathology. Also, the exact effects of
TGF-β signaling are suggested to depend on the developmen-
tal origin of aortic VSMCs.
The Renin-Angiotensin System and Its
Interaction with the TGF-β Signaling Pathway
in Thoracic Aneurysm Formation
Another system that has repeatedly been reported to play an
essential role in TAAs is RAS, which is a critical regulator of
blood pressure, extracellular fluid homeostasis and electrolyte
balance (Fig. 2). Ang II, the principal effector of the RAS, can
stimulate both the Ang II type 1 receptor (AT1R) and the Ang
II type 2 receptor (AT2R), but mainly acts via the former to
exert its well-known functions, such as vasoconstriction, fi-
brosis and inflammation [14, 15]. Notably, infusion of Ang II
leads to aneurysm formation of the abdominal aorta in apoli-
poprotein E-deficient mice [123, 124], but also to rapid ex-
pansion of the thoracic aorta with typical histological alter-
ations, such as elastin fragmentation and increased medial
thickness [123, 125, 126]. Additionally, increased plasma
Ang II concentrations are observed in TAA patients [127,
128]. Interestingly, blockade of Ang II-AT1R signaling atten-
uated aortic root expansion in multiple preclinical and clinical
studies [37, 106, 129, 130]. This stresses the importance of
RAS in thoracic aortic pathology. Figure 3 summarizes sev-
eral mechanisms by which the RAS may influence aneurys-
mal disease, which is discussed in more detail below.
AT1R Signaling
As stated, Ang II mainly exerts its effects via the AT1R, which
could contribute to TAA formation. An important aspect is
also where exactly the vascular AT1Rs relevant for signaling
in TAAs are located. Unlike humans, rodents have 2 types of
AT1R (a and b). VSMC-specific deletion of the most abun-
dant subtype (AT1aR) did not affect aortic pathology in
Fbn1mgR/mgR mice [131], nor in an ascending aortic aneurysm
model (LDL receptor−/− mice fed a saturated fat diet and in-
fused with Ang II) [132]. Thus, either the relevant AT1R are
located on other vascular cells (endothelial cells and/or fibro-
blasts) [131–133], or continued AT1R stimulation via remain-
ing AT1bR might occur. In case of the former, a likely
scenario is that VSMCs are affected by factors released from
other vascular cells following their stimulation by Ang II. To
rule out the latter, mice lacking both AT1R subtypes in
VSMCs need to be studied.
AT2R Signaling
AT2R stimulation is generally regarded to counter-regulate
the effects mediated by the AT1R [15]. One of the rationales
behind the therapeutic usage of ARBs is that the upregulated
Ang II during RAS blockade is redirected from the blocked
AT1R to the non-blocked AT2R to activate alternative tran-
scriptional programs. This yields protection in numerous car-
diovascular conditions, such as hypertension and heart failure.























Fig. 2 The renin-angiotensin system (RAS) and RAS blocking agents.
Kidney-derived renin cleaves liver-derived angiotensinogen to
generate angiotensin I, which is subsequently converted by angiotensin-
converting enzyme (ACE) to angiotensin II, the main effector of the RAS.
Angiotensin II stimulates its type 1 and 2 receptors, resulting in opposing
effects on vasoactivity, fibrosis, and inflammation [14, 15]. RAS inhibi-
tion is possible with renin inhibitors, ACE inhibitors, and angiotensin II
type 1 receptor blockers
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controversial [134]. On the one hand, previous studies dem-
onstrated that the ability of the ARB losartan to attenuate
aortic enlargement required availability of AT2R signaling
[135]. Also, knock-out of the AT2R gene resulted in larger
aortic diameters and an increased number of premature deaths
in Fbn1C1041G/+ mice [37]. As the exact causes of deaths in
this study were not provided, it remains uncertain if these
could be attributed to aortic complications, such as aortic dis-
section and rupture. In addition, renin inhibitors (RI) and
angiotensin-converting enzyme inhibitors (ACEi), blocking
both AT1R and AT2R signaling (Fig. 2), were less effective
than ARBs in decreasing aortic root dilatation in Fbln4R/R
[136] and Fbn1C1041G/+ mice [37] and preventing transverse
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Fig. 3 Hypothesized mechanism involving TGF-β signaling, RAS and
disturbed mechanosensing abilities of aortic VSMCs that leads to TAA in
syndromic individuals. Normally, TGF-β signaling, RAS, and
mechanosensing in aortic VSMCs, via elastin-contractile units, cooperate
to control aortic ECM remodeling and to maintain ECM integrity.
However, in the situation of syndromic aneurysmal disease involving
mutations in constituents of the ECM or the elastin-contractile unit,
mechanosensing abilities are disturbed (1). This leads to mechanical
stress, which stimulates local RAS activity by inducing ACE expression
and activating the AT1R (2). Also, alternative, less-characterized mech-
anisms that stimulate local RAS activity might come into play in TAA
formation. This increased RAS signaling can act as an upstream activator
of TGF-β signaling (3) but also directly increase ERK1/2 signaling (4). In
turn, TGF-β hyperactivity induces both canonical TGF-β signaling and
non-canonical ERK1/2 signaling. Consequently, expression of target
genes, among them MMPs and profibrotic factors such as connective
tissue growth factor (CTGF) and PAI-1 is highly increased (5).
Eventually, overexpression of these factors can lead to detrimental
ECM degradation and aortic stiffness (6), which contributes to aortic
aneurysm formation in affected syndromic individuals. In turn, ECM
degradation leads to higher bioavailability of sequestered TGF-β, further
amplifying this process
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mice [135]. Of note, only single dosages of these classes of
drugs were investigated and other dosages might have
yielded different outcomes. Nonetheless, these results ad-
vocate a protective role of the AT2R in aneurysm forma-
tion. On the other hand, a recent study demonstrated that
direct AT2R stimulation with the AT2R agonist C21 did
not show beneficial effects on TAAs in Fbn1C1041G/+ mice
[137]. In line with this, blockade of the AT2R did not ac-
celerate Ang II-induced aneurysm growth in hypercholes-
terolemic mice [123]. Lastly, losartan continued to exert
beneficial effects on aortic pathology after deletion of the
AT2R in mice harboring a VSMC-specific knock-out of
Fbln4 [100]. This indicates that AT2R activation in combi-
nation with AT1R blockade is only essential to yield pro-
tective effects under specific genetic conditions. Of note,
the animal models in these studies display wide heteroge-
neity and the role of the AT2R in aortic pathology could
depend on the exact genetic background, the mechanism by
which the aneurysm is induced and timing and duration of
treatment. In the human situation, most tissues display low
AT2R expression, except during embryonic development
[138]. Although AT2R upregulation is reported under path-
ological conditions, which could include aortic diseases
[139], it is also possible that AT2R signaling comes into
play at a later stage of aortic aneurysm development and is
not involved in its initial pathogenesis [136].
Interaction with TGF-β Signaling
The RAS interacts with TGF-β signaling at multiple levels
and this might compose a mechanism by which it contributes
to thoracic aortic pathology. Importantly, Ang II-AT1R sig-
naling acts as an upstream activator of TGF-β signaling: Ang
II directly increases TGF-β mRNA production, TGF-β pro-
tein expression and TGF-β activity [13, 140, 141]. As various
TAA syndromes such as MFS and LDS are characterized by
increased TGF-β signaling, this could be secondary to elevat-
ed RAS signaling. Indeed, abnormal upregulation of ACE and
subsequent elevated local Ang II-AT1R signaling has been
demonstrated in mice harboring a VSMC-specific knock-out
of Fbln4, leading to ascending aortic aneurysms [100]. Also,
enhanced AT1R downstream responses to Ang II stimulation
are observed in Fbln4-deficient VSMCs [17]. Theoretically,
increased RAS signaling in the context of aortic aneurysms
could also be due to increased receptor density of the AT1R.
However, to the best of our knowledge, this has not been
studied in human TAAs yet.
Perturbed Mechanosensing
One of the mechanisms that could lead to increased Ang II-
AT1R signaling in syndromic TAAs is mechanical stress due
to perturbations in mechanosensing. The aortic wall is
continuously subjected to varying hemodynamic loads,
such as a pulsatile blood pressure [142]. Normally, these
mechanical forces are sensed by aortic VSMCs via
elastin-contractile units (Fig. 3), which are composed of
intracellular contractile elements linked to elastic fibers
and microfibrils in the aortic ECM via focal adhesions
[143]. In response to these mechanical cues, VSMCs ac-
tivate downstream targets (mechanosensing molecules)
which alter downstream gene expression to influence the
composition of the ECM. Sensing the biomechanical en-
vironment (mechanosensing) and propagation of this sig-
nal intracellularly (mechanotransduction) to remodel the
ECM under various hemodynamic circumstances are es-
sential to ensure sufficient strength and compliance of the
aortic wall and to maintain aortic wall integrity [143].
Consequently, genetic mutations in components of the
elastin-contractile units, such as fibrillin-1, fibulin-4, and
α-actin, lead to perturbed mechanosensing and result in
inadequate ECM remodeling and mechanical stress. This
predisposes to aortic aneurysms [17, 60, 101, 144] (Fig.
3). In addition, these abnormalities in mechanosensing are
paralleled by elevated local ACE expression and in-
creased Ang II signaling [100]. This could be a conse-
quence of the resulting mechanical stress, which has been
demonstrated to upregulate local ACE expression [145]
and to even directly stimulate the AT1R, in an Ang II-
independent manner [146, 147]. Therefore, it is most like-
ly that elevated AT1R signaling in TAAs can best be
prevented by ARBs and not by ACEi, as the latter can
only prevent Ang II formation and not Ang II-
independent AT1R signaling.
Abnormalities inmechanosensing lead to increased expres-
sion of mechanosensing molecules, which could further con-
tribute to elevated TGF-β signaling, as observed in syndromic
aortic aneurysms [17, 68, 148–150]. For instance, the
mechanosensing molecule early growth response 1 (EGR1)
has been shown to increase TGF-β gene expression by bind-
ing to its promotor and activating its transcription. Also,
EGR1 induces expression of thrombospondin (Thbs1), anoth-
er mechanosensing molecule that disturbs arterial wall integ-
rity, activates ERK1/2 and latent TGF-β, and serves as an
important mediator of Ang II-induced activation of TGF-β
in rat cardiac fibroblasts and mesangial cells [13, 17].
Notably, deletion of Thbs1 in mice harboring a VSMC-
specific knock-out of Fbln4 largely prevented TAA formation
[17]. Thus, abnormal mechanosensing could contribute to aor-
tic aneurysms by (1) hampering adequate ECM remodeling in
response to hemodynamic loads, and (2) stimulation of local
AT1R and TGF-β signaling pathways, via mechanisms that
involve mechanical stress and pathological upregulation of
mechanosensing molecules (Fig. 3). Nonetheless, much of
these mechanisms remain only partly understood and require
further research.
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ERK1/2 Signaling: Crosstalk Between RAS and TGF-β
An important question that remains is how elevated Ang II-
ERK1/2 and TGF-β signaling drive aneurysmal disease. The
mitogen-activated protein kinase (MAPK) signaling pathway
forms an important crosstalk between RAS and TGF-β sig-
naling: both Ang II and TGF-β, via non-canonical signaling,
activate the 3 major MAP kinases: ERK1/2, JNK and p38 [36,
127]. Of these kinases, particularly ERK1/2 seems to be in-
volved in aortic aneurysm formation, as the MAPK kinase
(MEK) 1/2 inhibitor RDEA119 attenuated aortic root growth
by selectively reducing ERK1/2 activation in Fbn1C1041G+
mice, without affecting JNK and p38 activity [38]. In this
study, ERK1/2-blockade was highly effective, as aortic root
growth in this group was even indistinguishable from wild-
type mice. Additionally, accumulation of phosphorylated
ERK1/2 (pERK1/2), the active form of ERK1/2, was associ-
ated with aneurysm growth in Fbn1C1041G+ mice, and both a
TGF-β neutralizing antibody and losartan were able to reduce
pERK1/2 levels and to attenuate aneurysm expansion [37].
Notably, the MAPK pathway has also been shown to directly
induce canonical TGF-β signaling by phosphorylation and
subsequent activation of R-SMAD proteins [36, 151], thereby
forming a positive feedback loop (Fig. 3).
TGF-β signaling induces expression of MMPs, such as
MMP2 andMMP9, in aortic VSMC [127, 152–154], predom-
inantly via non-canonical signaling pathways including
ERK1/2 [155]. MMPs are involved in the degradation of
ECM components and their activity is normally balanced by
antagonizing tissue inhibitors of MMPs (TIMPs) to strictly
control ECM turnover. Elevated TGF-β- and ERK1/2-
induced MMP expression results in increased remodeling
and incremental degradation of aortic connective tissue, which
leads to weakness of the aortic wall. Consequently, the aortic
capacity to endure biomechanical forces is reduced, which
predisposes to aneurysm development [57, 153]. Indeed, a
signature of elevated MMP expression is found in tissue sam-
ples from TAA patients [153, 156]. MMP inhibition could
therefore have therapeutic potential, as evidenced by the ob-
servation that the MMP inhibitor doxycycline was more po-
tent in preventing TAA and to preserve elastic fiber integrity
than the β-blocker atenolol in Fbn1C1041G+ mice [157]. The
beneficial effects of doxycycline on thoracic aortic pathology
were also observed in other MFS mouse models
(Fbn1C1041G/+ and Fbn1mgR/mgR) [158, 159]. However,
MMPs do not seem to contribute to TAAs under all circum-
stances, as another preclinical study demonstrated that
MMP2-deficiency actually accelerated dilatation of the tho-
racic aorta during Ang II infusion. Although this model may
not fully mimic syndromic TAA patients, it demonstrates that
a balance between Ang II and MMPs is essential to maintain
ECM homeostasis. Another mechanism by which MMPs
could contribute to aneurysm formation is by further
increasing TGF-β signaling [30]. This is evidenced by the
observation that activation of TGF-β and subsequent activa-
tion of the pSMAD2/3 pathway was hampered in MMP2-de-
ficient mice [160]. Besides, TGF-β is normally sequestered in
the ECM and increased ECM degradation mediated byMMPs
could result in a greater TGF-β bioavailability [62]. Next to
increased MMP expression, both AT1R signaling and TGF-β
increase genetic expression of several profibrotic factors, such
as connective tissue growth factor and plasminogen activator
inhibitor-1 [161]. These factors may further impair aortic wall
homeostasis by increasing aortic wall stiffness [161], which is
an independent predictor of progressive aortic dilatation in
MFS patients [162].
As stated, blockade of TGF-β signaling too early exac-
erbates aortic pathology [114]. Therefore, a better approach
might be to specifically inhibit Ang II-AT1R-driven TGF-β
overactivation, rather than TGF-β signaling in general.
ARBs antagonize TGF-β overexpression in mice with
chronic renal insufficiency and cardiomyopathy [163,
164]. Additionally, mechanical stress from disruptions in
mechanosensing could theoretically be reduced by drugs
that decrease hemodynamic load, such as β-blockers or
alternative antihypertensive drugs.
Clinical Trials in Syndromic TAA Patients
Over the past 2 decades, multiple randomized controlled trials
have been performed to investigate the potency of ARBs and
β-blockers to limit aortic aneurysm growth in the clinical
situation (Table 3). Of note, all studies were performed in
MFS patients and most trials used aortic (root) growth as a
surrogate outcome for aneurysm rupture or dissection.
Brooke et al. [165] were the first to examine the clinical
benefits of ARBs on TAA pathology. In a retrospective study,
they demonstrated that ARB usage was associated with re-
duced aortic root growth in severely affected pediatric MFS
patients. Multiple randomized controlled trials followed [129,
130, 166–171] (Table 3). In 2013, the randomized open-label
controlled COMPARE trial was published, which investigat-
ed the potential benefit of adding losartan to standard care,
including a β-blocker in > 70% of the patients [129]. After
3 years of follow-up, aortic root aneurysm growth was signif-
icantly lower in the losartan group vs. the standard care group,
confirming the previous retrospective results [165]. Although
mean arterial blood pressure was slightly lower in the losartan
group, no correlation between blood pressure levels and aortic
root dimensions was found. This suggests that the beneficial
effects of losartan are, at least partially, independent of its
effects on blood pressure. This might be attributed to its in-
hibitory effects on TGF-β and ERK1/2-signaling, but clinical




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Several trials compared the efficacy of ARBmonotherapy with
β-blocker monotherapy to prevent aortic root expansion in
MFS patients [167, 169, 172]. This is particularly interesting
as the usage ofβ-blockers, the current mainstay of treatment, is
predominantly based on the results of a single clinical trial,
published in 1994 [173]. This trial had many limitations, such
as a very limited sample size, unblinded treatment allocation, a
lack of control on drug compliance and inclusion of deaths in
the analyses that were unrelated to aortic pathology [174].
Also, a recent Cochrane review stated that no clear treatment
recommendation regarding the use ofβ-blockers inMFS could
be made [175]. Therefore, solid evidence of the beneficial ef-
fects of β-blockers in MFS patients is lacking [176]. Notably,
none of the performed trials reported superiority of β-blockers
over ARBs. The largest among them, the Pediatric Heart
Network Trial [167], compared losartan with the β-blocker
atenolol in 608 young MFS patients. After 3 years of follow-
up, both drugs were equally effective in attenuating aortic root
dilatation. These results were verified by a Spanish randomized
controlled trial with a similar design [169]. Nonetheless, a re-
cent review [177] suggests that caution concerning ARBs as
first-line monotherapy is warranted, as adverse events were
almost twice as common in the losartan group compared to
the atenolol group in the Pediatric Heart Network Trial.
However, in the Spanish randomized controlled trial, only 1
serious adverse event occurred in the losartan group, compared
with 4 in the atenolol group [169]. Importantly, neither trials
reached statistical significance regarding these adverse end-
points [167, 169]. In addition, an extension study of the
Spanish trial by Forteza et al. found no differences in adverse
outcomes in the losartan vs. the atenolol group after a median
follow-up period of 6.7 years [178]. Thus, ARBs do not seem
to be inferior to β-blockers in attenuating aortic root growth in
MFS patients and display a similar long-term safety profile.
ARBs and β-Blockers: Synergy?
Interestingly, other studies examined potential synergistic ef-
fects of combining a β-blocker with an ARB in syndromic
TAAs. Although a synergy between β-blockers and ARBs
was observed in a small, open-label randomized controlled
trial [166], the beneficial effects of add-on losartan therapy
were not confirmed by the Ghent Marfan Trial [170].
Perhaps this study was underpowered, but the much larger
French Marfan Sartan trial also failed to confirm this synergy
[168]. In this latter study, 86% of the 303 included MFS pa-
tients used β-blocker therapy at baseline. After a median
follow-up of 3.5 years, the addition of 50–100 mg losartan
did not result in a slower dilatation of the aortic root compared
with placebo. Notably, this lack of synergy between ARBs
and β-blockers was challenged by the COMPARE trial
[129] and, more recently, by the multicenter randomized con-
trolled AIMS trial [130]. The AIMS trial demonstrated that
addition of the ARB irbesartan to usual care significantly de-
creased aortic root growth compared to placebo. In this add-on
irbesartan group, 54% used concomitant β-blocker therapy
and mean blood pressure levels were slightly lower, which
could contribute to the observed differences.
Notably, all randomized clinical trials examined aortic di-
latation, but none had sufficient statistical power to detect any
differences in the clinically most relevant outcomes, such as
aortic dissection, aortic rupture and mortality. Therefore, the
results from the recently published long-term follow-up study
of the COMPARE trial are highly relevant [179]. After a me-
dian follow-up period of 8 years, a clear reduction in several
adverse clinical endpoints, such as all-cause mortality and
aortic dissection, was observed in the patient group that used
losartan during the entire follow-up period. Interestingly, 81%
of these patients used concomitant β-blockade therapy. In
addition, a recent meta-analysis demonstrated that the addition
of an ARB to β-blocker therapy reduced the rate of aortic root
dilatation, but did not significantly reduce the number of aortic
complications [180]. This latter result could be a consequence
of low statistical power to demonstrate differences in these
complications due to low event rates. Also, this meta-
analysis did not include the long-term follow-up study from
the COMPARE trial [179]. Thus, when taking the results from
the COMPARE, AIMS, and the long-term follow-up study of
the COMPARE trial together, it seems that combining ARBs
and β-blockers in MFS patients is not only preferential to
prevent aneurysm growth but also to prevent long-term ad-
verse outcomes [129, 130, 179].
Differences Between Preclinical and Clinical Studies
Unfortunately, the promising preclinical results of ARBs to
attenuate TAA expansion [37, 106] were not unequivocally
reproduced in the clinical setting and the observed discrepan-
cy was remarkable. Several reasons could underlie the seem-
ingly lack of consistent results in the human situation. Firstly,
the efficacy of ARB treatment might be determined by the
type and dosage of ARB used. The AIMS trial demonstrated
that addition of irbesartan to usual care was beneficial, where-
as losartan did not lead to superior treatment outcomes in the
Marfan Sartan Trial. As irbesartan has a much longer half-life
and a greater bioavailability than losartan [181], this could
indicate that losartan dosages in previous studies were insuf-
ficient to fully benefit from its protective effects. Indeed, aten-
olol was administered in much higher dosages than losartan in
the Pediatric Heart Network Trial which led the authors to
conclude that a higher dose of losartan or a different ARB
might yield superior results [167]. Previously, it has been sug-
gested that administered dosages of RAS inhibitors, including
ARBs, in the range to reduce blood pressure are insufficient to
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effectively normalize TGF-β overexpression [182]. Provided
that these higher ARB dosages are well-tolerated by the in-
cluded patients, it would be interesting to study if these higher
dosages can attenuate aortic dilatation more effectively.
Secondly, it could be essential to start ARB treatment early in
aneurysm development. We hypothesize that elevated aortic
Ang II-AT1R signaling is an important driver for excessive
TGF-β signaling in the context of syndromic TAAs.
Consequently, early specific inhibition of Ang II-AT1R signal-
ing is necessary to prevent this detrimental TGF-β upregulation,
but still allowing for RAS-independent basal TGF-β signaling
to occur. Indeed, a preclinical study demonstrated that losartan
prevented aneurysm formation in a VSMC-specific Fbln4
knock-out mouse model when initiated from postnatal day 7,
whereas this treatment lost its efficacy when initiated at a later
time point [100]. Also, in the hallmark trial showing the benefi-
cial effect of losartan in Fbn1C1041G/+ mice, this treatment was
started prenatally [106]. How this critical treatment timewindow
can be translated to the human situation needs further investiga-
tion. Also, determinants other than age, such as aortic root Z-
scores, may be better indicators when to initiate medical treat-
ment, as they better reflect aortic disease stage. In addition,
higher circulating TGF-β levels are associated with more ad-
vanced stages and higher rates of aortic dilatation in TAA pa-
tients [149]. In this regard, it would be interesting to investigate
if circulating TGF-β levels could be used as a biomarker for the
severity of aortic pathology, in concordance with other possible
biomarkers [183]. Of note, factors other than Ang II can also
directly stimulate the AT1R in syndromic TAAs, such as me-
chanical stress due to disturbed mechanosensing. Therefore,
specific direct inhibition of AT1R signaling via ARBs, rather
than inhibition of Ang II via ACEi, is supposed to yield themost
optimal treatment outcomes, although a direct comparison has
not been made in syndromic TAA patients.
Thirdly, results from preclinical studies are based on a lim-
ited number of mouse models, harboring identical mutations
in the Fbn1 gene (Table 1) [14]. In contrast, more than 1000
mutations in FBN1 have been identified in human MFS pa-
tients [184, 185]. Therefore, these preclinical studies do not
adequately represent the genetic heterogeneity found in MFS
patients and this could hamper the translation of promising
preclinical results into the clinical situation.
Fourthly, this genetic heterogeneity in MFS patients can
also be an underlying cause for the differences in treatment
outcomes observed between clinical trials. Most clinical stud-
ies did not assess nor stratify for the underlying FBN1 muta-
tion. As a consequence, these mutations might not be equally
distributed among treatment groups and between different
studies. Of note, characterizing the underlyingFBN1mutation
is extremely relevant, as the type of mutation determines the
clinical course and severity of aortic pathology in MFS pa-
tients [186, 187]. Also, it predicts the efficacy of losartan
therapy: in a substudy of the COMPARE trial, MFS patients
carrying a haploinsufficient FBN1 mutation responded better
to losartan therapy than those harboring a dominant-negative
mutation [188]. Therefore, differences in underlying FBN1
mutations could be another reason for the observed variability
of treatment effects in clinical trials.
To summarize, multiple factors seem to underlie the ob-
served differences between the preclinical and clinical situa-
tion. Therefore, the results from the announced prospective
meta-analysis, combining all previous randomized controlled
trials on ARB and β-blocker treatment in MFS, are eagerly
awaited [189]. Hopefully, this meta-analysis will clarify the
therapeutic potential of these compounds in different MFS
subgroups, such as clustered by age, aortic Z-score, or type
of FBN1-mutation, on the most relevant clinical outcomes.
Conclusions and Future Directions
Over the past decades, a better understanding of the molecular
mechanisms leading to the formation of syndromic TAAs has
been obtained. Elevated signaling of the TGF-β pathway is
observed in syndromic TAA patients, which could be due to
increased local RAS signaling. These pathways are likely to
act in concert to induce aortic pathology by mechanisms that
remain subject of investigation, but at least include stimulation
of aortic ECM degradation and aortic fibrosis. However, how
elevated RAS signaling occurs in the context of TAAs is yet to
be fully elucidated. Mechanical stress resulting from disrup-
tion in mechanosensing abilities of aortic VSMCs might be
one of the contributors. Importantly, preclinical evidence sug-
gests that targeting the TGF-β pathway too early in aortic
aneurysm formation leads to worsening of aortic pathology.
Thus, clinical treatment in affected TAA patients should ide-
ally be directed at both RAS and TGF-β signaling, although
sparing the early protective role of the latter. In this regard,
biomarkers indicating the stage of aortic disease could be of
additional value. Also, higher ARB dosages combined with
therapeutic modalities that reduce mechanical stress, such as
β-blockers, might be preferential. As ERK1/2 also seems to
play a crucial role, an alternative treatment strategy might be
to specifically inhibit ERK1/2-signaling in syndromic TAAs
patients. Such drugs are currently being investigated in the
field of oncology [190].
Importantly, to the best of our knowledge, all clinical trials
investigating the efficacy of ARBs and β-blockers on aortic
pathologywere performed inMFS individuals. Unfortunately,
these clinical trials did not confirm the promising results from
preclinical studies. Several reasons could underlie these dif-
ferences, including wide genetic heterogeneity among the
MFS population, which affects disease severity and treatment
efficacy. Hopefully, future research will take these genetic
aspects into account. A difficulty to overcome is the fact that
only a limited number of patients for each specific mutation
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are available. Also in this light, caution is warranted regarding
the extrapolation of results from the MFS study population to
patients with other TAA syndromes, such as LDS, and more
research is needed in these individual patients and patient
populations. In this regard, bioinformatic predictions on the
consequences of different mutations might be useful to form
more specific, but large enough study groups and investigate
treatment outcomes in these subgroups. This knowledge can
be combined with new developments in induced pluripotent
stem cells technology, for which patient material can be used
to improve and accelerate the translation of preclinical find-
ings into the clinical situation [191]. Combining these tech-
niques with new integrative approaches coupling genomics,
transcriptomics, proteomics, and functional experiments [62,
192] could pave the way for novel targeted and more individ-
ualized treatment regimens for syndromic TAA patients.
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